Understanding attitudes and obstacles to vaccination against COVID-19 in patients with primary immunodeficiency.

Background: Patients with primary immunodeficiency (PID) are at increased risk for infections such as SARS-CoV-2 (COVID-19), due to the nature of their diseases and being immunocompromised. At this time, four vaccines against COVID-19 (Pfizer-BioNtech's Comirnaty, Moderna's Spikevax, AstraZeneca's Vaxzevria, Johnson & Johnson's Janssen) have been approved for use by Health Canada. Due to the novelty of these vaccines, clinical studies in patients with PID are ongoing.